Sangamo BioSciences Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
BMO Capital Starts Sangamo BioSciences (SGMO) at Outperform
April 22, 2015 4:31 PM EDTBMO Capital initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $19.00.
Analyst Jim Birchenough commented, "Our favorable outlook is based on its novel and proprietary approach to gene editing, a deep pipeline of gene therapy opportunities with competitive advantage,... More
Sangamo Biosciences (SGMO) Tops Q1 EPS by 6c
April 22, 2015 4:13 PM EDTSangamo Biosciences (NASDAQ: SGMO) reported Q1 EPS of ($0.08), $0.06 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.5 million.
For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.
... More


